{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T11:35:55Z","timestamp":1774870555787,"version":"3.50.1"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","cancertreatmentreviews.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.ctrv.2017.09.002","type":"journal-article","created":{"date-parts":[[2017,9,18]],"date-time":"2017-09-18T17:32:04Z","timestamp":1505755924000},"page":"120-129","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["Peripheral T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease"],"prefix":"10.1016","volume":"60","author":[{"given":"Alessandro","family":"Broccoli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Argnani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pier Luigi","family":"Zinzani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2017.09.002_b0005","series-title":"Postgraduate hematology","first-page":"524","article-title":"T-cell lymphoproliferative disorders","author":"Zinzani","year":"2016"},{"key":"10.1016\/j.ctrv.2017.09.002_b0010","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International T-Cell Lymphoma Project. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.09.002_b0015","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","article-title":"Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry","volume":"124","author":"Ellin","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2017.09.002_b0020","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2017.09.002_b0025","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1182\/blood-2013-11-536359","article-title":"Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma","volume":"123","author":"Iqbal","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2017.09.002_b0030","doi-asserted-by":"crossref","first-page":"e214","DOI":"10.1038\/bcj.2014.34","article-title":"The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas","volume":"4","author":"Briski","year":"2014","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.ctrv.2017.09.002_b0035","doi-asserted-by":"crossref","first-page":"783","DOI":"10.3109\/10428194.2016.1140760","article-title":"How to select the frontline treatment for a patient with peripheral T-cell lymphoma","volume":"57","author":"Ansell","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ctrv.2017.09.002_b0040","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/annonc\/mds643","article-title":"ESMO consensus conferences: guidelines on malignant lymphoma. Part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma","volume":"24","author":"Dreyling","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2017.09.002_b0045","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2008.17.4870","article-title":"Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicentre study","volume":"27","author":"Reimer","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.09.002_b0050","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","article-title":"Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01","volume":"30","author":"d\u2019Amore","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.09.002_b0055","doi-asserted-by":"crossref","first-page":"e452","DOI":"10.1038\/bcj.2016.63","article-title":"First-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation","volume":"6","author":"Wilhelm","year":"2016","journal-title":"Blood Cancer J"},{"issue":"16","key":"10.1016\/j.ctrv.2017.09.002_b0060","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","article-title":"Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors","volume":"31","author":"Mak","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.09.002_b0065","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1080\/1042819031000077124","article-title":"Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression","volume":"44","author":"Wang","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ctrv.2017.09.002_b0070","doi-asserted-by":"crossref","first-page":"6657","DOI":"10.1158\/1078-0432.CCR-12-2251","article-title":"Pralatrexate pharmacology and clinical development","volume":"19","author":"Marchi","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2017.09.002_b0075","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.1200\/JCO.2008.20.8470","article-title":"Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies","volume":"27","author":"O\u2019Connor","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.09.002_b0080","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study","volume":"29","author":"O\u2019Connor","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.09.002_b0085","doi-asserted-by":"crossref","first-page":"4921","DOI":"10.1158\/1078-0432.CCR-10-1214","article-title":"Folotyn (pralatrexate injection) for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma: U.S. Food and Drug Administration drug approval summary","volume":"16","author":"Malik","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2017.09.002_b0090","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1158\/1535-7163.MCT-07-2256","article-title":"Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin","volume":"7","author":"Newbold","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ctrv.2017.09.002_b0095","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrd2133","article-title":"Anticancer activities of histone deacetylase inhibitors","volume":"5","author":"Bolden","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ctrv.2017.09.002_b0100","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1093\/jnci\/92.15.1210","article-title":"Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells","volume":"92","author":"Marks","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2017.09.002_b0105","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S1535-6108(03)00165-X","article-title":"Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?","volume":"4","author":"Johnstone","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ctrv.2017.09.002_b0110","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/bjh.13400","article-title":"Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data","volume":"170","author":"Bates","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2017.09.002_b0115","doi-asserted-by":"crossref","first-page":"e357","DOI":"10.1038\/bcj.2015.83","article-title":"Romidepsin targets multiple survival signalling pathways in malignant T cells","volume":"5","author":"Valdez","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.ctrv.2017.09.002_b0120","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1182\/blood-2010-10-312603","article-title":"Phase II trial of romidepsin in patients with peripheral T-cell lymphoma","volume":"117","author":"Piekarz","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2017.09.002_b0125","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1200\/JCO.2008.21.6150","article-title":"Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma","volume":"27","author":"Piekarz","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.09.002_b0130","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.09.002_b0135","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1756-8722-7-11","article-title":"Romidepsin for the treatment of relapsed\/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses","volume":"7","author":"Coiffier","year":"2014","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.ctrv.2017.09.002_b0140","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13045-016-0243-8","article-title":"Romidepsin for the treatment of relapsed\/refractory peripheral T-cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial","volume":"9","author":"Foss","year":"2016","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.ctrv.2017.09.002_b0145","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/2050-7771-2-16","article-title":"Tolerability to romidepsin in patients with relapsed\/refractory T-cell lymphoma","volume":"2","author":"Foss","year":"2014","journal-title":"Biomarkers Res"},{"key":"10.1016\/j.ctrv.2017.09.002_b0150","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/cam4.467","article-title":"Electrocardiographic effects of class 1 selective histone deacetylase inhibitor romidepsin","volume":"4","author":"Sager","year":"2015","journal-title":"Cancer Med"},{"key":"10.1016\/j.ctrv.2017.09.002_b0155","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1182\/blood-2003-01-0039","article-title":"CAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity","volume":"102","author":"Francisco","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2017.09.002_b0160","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.3324\/haematol.2013.084913","article-title":"CD30 expression in peripheral T-cell lymphoma","volume":"98","author":"Sabattini","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.ctrv.2017.09.002_b0165","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1182\/blood-2014-07-584953","article-title":"Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels","volume":"124","author":"Bossard","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2017.09.002_b0170","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","article-title":"Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas","volume":"363","author":"Younes","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2017.09.002_b0175","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.09.002_b0180","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.critrevonc.2015.03.011","article-title":"Experience of brentuximab vedotin in relapsed\/refractory Hodgkin lymphoma and relapsed\/recfractory systemic anaplastic large-cell lymphoma in the Named Patient Program: review of the literature","volume":"95","author":"Zinzani","year":"2015","journal-title":"Crit Rev Hematol Oncol"},{"key":"10.1016\/j.ctrv.2017.09.002_b0185","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","article-title":"Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin","volume":"123","author":"Horwitz","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2017.09.002_b0190","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.3324\/haematol.2015.135400","article-title":"Brentuximab vedotin in refractory or relapsed peripheral T-cell lymphomas: the French named patient program experience in 56 patients","volume":"101","author":"Lamarque","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.ctrv.2017.09.002_b0195","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1158\/1078-0432.CCR-07-1786","article-title":"A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors","volume":"14","author":"Steele","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2017.09.002_b0200","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bjh.13222","article-title":"A phase II trial of belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma","volume":"168","author":"Foss","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2017.09.002_b0205","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study","volume":"33","author":"O\u2019Connor","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.09.002_b0210","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1158\/1078-0432.CCR-14-3119","article-title":"FDA approval: belinostat for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma","volume":"21","author":"Lee","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2017.09.002_b0215","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1093\/annonc\/mdp508","article-title":"Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome","volume":"21","author":"Zinzani","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2017.09.002_b0220","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3324\/haematol.10737","article-title":"Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience","volume":"92","author":"Arkenau","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.ctrv.2017.09.002_b0225","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1158\/1078-0432.CCR-07-1061","article-title":"Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents","volume":"14","author":"Leoni","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2017.09.002_b0230","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1200\/JCO.2012.43.7285","article-title":"Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial","volume":"31","author":"Damaj","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.09.002_b0235","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1182\/blood-2014-11-567792","article-title":"Lenalidomide in non-Hodgkin lymphoma: biological perspectives and therapeutic opportunities","volume":"125","author":"Kritharis","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2017.09.002_b0240","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.3109\/10428194.2011.573031","article-title":"Lenalidomide monotherapy for relapsed\/refractory peripheral T-cell lymphoma not otherwise specified","volume":"52","author":"Zinzani","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ctrv.2017.09.002_b0245","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1016\/j.ejca.2013.04.029","article-title":"A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid\u00ae) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial","volume":"49","author":"Morschhauser","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2017.09.002_b0250","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/cncr.29103","article-title":"Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma","volume":"121","author":"Toumishey","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2017.09.002_b0255","first-page":"803a","article-title":"Duvelisib (IPI-145), a phosphoinositide-3-kinase-\u03b4,\u03b3 inhibitor, shows activity in patients with relapsed\/refractory T-cell lymphoma","volume":"124","author":"Horwitz","year":"2014","journal-title":"Blood (ASH annual meeting abstracts)"},{"key":"10.1016\/j.ctrv.2017.09.002_b0260","first-page":"87a","article-title":"Preliminary results of a phase II study of single agent BAY 80\u20136946, a novel PI3K inhibitor, in patients with relapsed\/refractory, indolent or aggressive lymphoma","volume":"122","author":"Dreyling","year":"2013","journal-title":"Blood (ASH annual meeting abstracts)"},{"key":"10.1016\/j.ctrv.2017.09.002_b0265","first-page":"60","article-title":"The aurora kinase family in cell division and cancer","volume":"1786","author":"Vader","year":"2008","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.ctrv.2017.09.002_b0270","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/modpathol.2012.211","article-title":"Differential expression of aurora-A kinase in T-cell lymphomas","volume":"26","author":"Kanagal-Shamanna","year":"2013","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ctrv.2017.09.002_b0275","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1200\/JCO.2014.60.6327","article-title":"Phase II intergroup trial of alisertib in relapsed and refractory peripheral T-cell lymphoma and transformed mycosis fungoides: SWOG 1108","volume":"33","author":"Barr","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.09.002_b0280","first-page":"341a","article-title":"First multicentre, randomized phase 3 study in patients (pts) with relapsed\/refractory (R\/R) peripheral T-cell lymphoma (PTCL): alisertib (MLN8237) versus investigator\u2019s choice (Lumiere trial; NCT01482962)","volume":"126","author":"O\u2019Connor","year":"2015","journal-title":"Blood (ASH annual meeting abstracts)"},{"key":"10.1016\/j.ctrv.2017.09.002_b0285","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1158\/1078-0432.CCR-09-2697","article-title":"Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia\/lymphoma","volume":"16","author":"Ishii","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2017.09.002_b0290","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1200\/JCO.2013.52.0924","article-title":"Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-CC chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma","volume":"32","author":"Ogura","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.09.002_b0295","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1200\/JCO.2011.37.3472","article-title":"Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicentre phase II study","volume":"30","author":"Ishida","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.09.002_b0300","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1200\/JCO.2009.25.3575","article-title":"Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma","volume":"28","author":"Yamamoto","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.09.002_b0305","doi-asserted-by":"crossref","first-page":"e407","DOI":"10.3324\/haematol.2016.146977","article-title":"European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed\/refractory peripheral T-cell lymphoma","volume":"101","author":"Zinzani","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.ctrv.2017.09.002_b0310","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40164-015-0002-5","article-title":"Selective inhibitors of nuclear export (SINE) in haematological malignancies","volume":"4","author":"Das","year":"2015","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.ctrv.2017.09.002_b0315","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.3324\/haematol.2012.074781","article-title":"Selective inhibitors of nuclear export for the treatment of non-Hodgkin\u2019s lymphomas","volume":"98","author":"Azmi","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.ctrv.2017.09.002_b0320","first-page":"396a","article-title":"The oral selective inhibitor of nuclear export (SINE) selinexor (KPT-330) demonstrates broad and durable clinical activity in relapsed\/refractory non Hodgkin\u2019s lymphoma (NHL)","volume":"124","author":"Kuruvilla","year":"2014","journal-title":"Blood (ASH annual meeting abstracts)"},{"key":"10.1016\/j.ctrv.2017.09.002_b0325","doi-asserted-by":"crossref","first-page":"523","DOI":"10.4161\/mabs.27398","article-title":"ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade","volume":"6","author":"Silence","year":"2014","journal-title":"MAbs"},{"key":"10.1016\/j.ctrv.2017.09.002_b0330","first-page":"3023a","article-title":"A phase I, first-in-human study of ARGX-110, a monoclonal antibody targeting CD70, a receptor involved in immune escape and tumor growth in patients with solid and hematologic malignancies","volume":"32","author":"Awada","year":"2014","journal-title":"J Clin Oncol (ASCO annual meeting abstracts)"},{"key":"10.1016\/j.ctrv.2017.09.002_b0335","first-page":"40a","article-title":"ARGX-110, a novel monoclonal antibody targeting CD70, is associated with biological activity in patients with relapsed\/recfractory T-cell lymphomas","volume":"33","author":"Maerevoet","year":"2015","journal-title":"Hematol Oncol (ICML meeting abstracts)"},{"key":"10.1016\/j.ctrv.2017.09.002_b0340","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13045-016-0266-1","article-title":"A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed\/refractory peripheral T-cell lymphoma patients","volume":"9","author":"Pellegrini","year":"2016","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.ctrv.2017.09.002_b0345","first-page":"3050a","article-title":"Phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma: updated results","volume":"124","author":"Holkova","year":"2014","journal-title":"Blood (ASH annual meeting abstracts)"},{"key":"10.1016\/j.ctrv.2017.09.002_b0350","doi-asserted-by":"crossref","DOI":"10.1080\/15384047.2016.1219820","article-title":"The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines","author":"Cosenza","year":"2016","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.ctrv.2017.09.002_b0355","first-page":"8582a","article-title":"A phase I\/II trial of the combination of romidepsin and lenalidomide in patients with relapsed\/refractory lymphoma and myeloma: Phase I results","volume":"32","author":"Lunning","year":"2014","journal-title":"J Clin Oncol (ASCO annual meeting abstracts)"},{"key":"10.1016\/j.ctrv.2017.09.002_b0360","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1158\/1078-0432.CCR-14-2249","article-title":"Preclinical pharmacologic evaluation of pralatrexate and romidepsin confirms potent synergy of the combination in a murine model of human T-cell lymphoma","volume":"21","author":"Jain","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2017.09.002_b0365","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1158\/1078-0432.CCR-15-0033","article-title":"Aurora A kinase inhibition selectively synergizes with histone deacetylase inhibitor through cytokinesis failure in T-cell lymphoma","volume":"21","author":"Zullo","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2017.09.002_b0370","first-page":"1744","article-title":"A phase I trial of alisertib plus romidepsin for relapsed\/refractory aggressive B- and T-cell lymphomas","volume":"124","author":"Fanale","year":"2014","journal-title":"Blood (ASH annual meeting abstracts)"},{"key":"10.1016\/j.ctrv.2017.09.002_b0375","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1158\/1078-0432.CCR-10-0671","article-title":"Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies","volume":"16","author":"Marchi","year":"2010","journal-title":"Cin Cancer Res"},{"key":"10.1016\/j.ctrv.2017.09.002_b0380","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.3346\/jkms.2016.31.7.1160","article-title":"Pralatrexate in combination with bortezomib for relapsed or refractory peripheral T cell lymphoma in 5 elderly patients","volume":"31","author":"Lee","year":"2016","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.ctrv.2017.09.002_b0385","first-page":"293a","article-title":"Brentuximab vedotin in combination with bendamustine for patients with Hodgkin lymphoma who are relapsed or refractory after frontline therapy","volume":"124","author":"LaCasce","year":"2014","journal-title":"Blood (ASH annual meeting abstracts)"},{"key":"10.1016\/j.ctrv.2017.09.002_b0390","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2017.09.002_b0395","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737217301469?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737217301469?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,27]],"date-time":"2018-08-27T11:56:38Z","timestamp":1535370998000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737217301469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":79,"alternative-id":["S0305737217301469"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2017.09.002","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Peripheral T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2017.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}